Significant reduction of tumor volume, augmentation of CD80 and CD86 on CD11c+ DCs, increased levels of CD8+ Granzyme B+ T cells, and CXCL16 mediated migration of CD8+ T cells in vivo. Here, ITGAX is linked to neoplasm.